Piper Jaffray Upgrades Anadys Pharmaceuticals (ANDS) to Overweight
Tweet Send to a FriendGet Alerts ANDS Hot Sheet
Price: $3.70 --0%
Rating Summary:
0 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 19
Rating Summary:
0 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 19
Trade ANDS Now!
Piper Jaffray & Co. upgrades Anadys Pharmaceuticals (Nasdaq: ANDS) from Neutral to Overweight. Price target $2.50.
Piper analyst says, "Early safety data and 4-week rapid viral response (RVR) rates are expected by year-end. Further data including 12-week early viral response (EVR) and the more critical safety assessment is expected to be reported in 1H:10. We are optimistic that 200mg BID ANA598 will show potent anti-viral activity without inducing rash leading to new partnering discussions. With positive 4-week efficacy data and a clean safety profile, Anadys should be able to get suitors back to the table for a partnership next year.
"We are upgrading to Overweight based on a projected enterprise value of $113 million (up from $94 million) by applying the same 5x multiple to 2015 projected ANA598 sales of $156 million discounted back at 50%. To this we add $10 million for ANA773 and YE:10E net cash...Risks include developmental, clinical, and regulatory. ANA598 may fail in clinical trials. Anadys may not enter new collaborations. The company could face unforeseen litigation and will need to raise additional capital this year."
To see more analyst ratings on ANDS Click Here.
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology.
Piper analyst says, "Early safety data and 4-week rapid viral response (RVR) rates are expected by year-end. Further data including 12-week early viral response (EVR) and the more critical safety assessment is expected to be reported in 1H:10. We are optimistic that 200mg BID ANA598 will show potent anti-viral activity without inducing rash leading to new partnering discussions. With positive 4-week efficacy data and a clean safety profile, Anadys should be able to get suitors back to the table for a partnership next year.
"We are upgrading to Overweight based on a projected enterprise value of $113 million (up from $94 million) by applying the same 5x multiple to 2015 projected ANA598 sales of $156 million discounted back at 50%. To this we add $10 million for ANA773 and YE:10E net cash...Risks include developmental, clinical, and regulatory. ANA598 may fail in clinical trials. Anadys may not enter new collaborations. The company could face unforeseen litigation and will need to raise additional capital this year."
To see more analyst ratings on ANDS Click Here.
Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology.
You May Also Be Interested In
- UPDATE: BofA/Merrill Lynch Upgrades Adobe (ADBE) to Buy
- Jefferies Boosts PT on Micron (MU) Post Q3; Sees 50% Upside
- UPDATE: Bernstein Cuts BlackBerry (BBRY) to Underperform; Notes Weak BB10 Traction
Create E-mail Alert Related Categories
UpgradesRelated Entities
Piper Jaffray
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
